Hiroshige Yoshioka
0000-0001-7724-0481
Publication & Citation Trends
Publications
349 total
Plasma Protein Analysis for Biomarker Discovery in Lung Cancer Treated With Atezolizumab Combination Therapy in J‐ TAIL ‐2
Cited by 0
Semantic Scholar
Clinical trajectory of KRAS G12C-mutated advanced non-small cell lung cancer: a single-center cohort study in Japan
Cited by 0
Semantic Scholar
Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset.
Cited by 5
Semantic Scholar
A single-arm, phase II study of sotorasib plus carboplatin/pemetrexed in advanced non-squamous non-small cell lung cancer patients with KRAS G12C mutation (WJOG14821L, SCARLET). OA
Cited by 8
Semantic Scholar
Skin disorder within 30 days is a favorable prognostic factor in patients with lung squamous cell carcinoma treated with necitumumab plus gemcitabine and cisplatin: a sub-analysis of the NINJA study OA
Cited by 0
Semantic Scholar
Turtle Study: A Phase 2 Study of Durvalumab Plus Carboplatin and Etoposide in Elderly Patients With Extensive-Stage SCLC (LOGiK 2003)
Cited by 1
Semantic Scholar
Atezolizumab + Chemotherapy for Advanced Non‐Small Cell Lung Cancer in Japanese Clinical Practice (J‐TAIL‐2)
Cited by 0
Semantic Scholar
Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834.
Cited by 18
Semantic Scholar
Research Topics
Lung Cancer Treatments and Mutations
(254)
Lung Cancer Diagnosis and Treatment
(147)
Lung Cancer Research Studies
(145)
Cancer Immunotherapy and Biomarkers
(65)
Colorectal Cancer Treatments and Studies
(49)
Affiliations
Kansai Medical University
Harbin Medical University
Kobe Medical Center
National Cancer Center
Kurashiki Central Hospital